Test Price
2,800 AED✅ Home Collection Available
KRAS Gene Mutation Analysis for Acute Myelogenous Leukemia, Genetic Test in UAE
Executive Summary & Core Metrics
This NGS-based KRAS gene mutation test delivers 99.9% diagnostic sensitivity for AML prognosis and targeted therapy selection. Processed in an ISO 9001:2015 accredited laboratory, the test includes VIP mobile phlebotomy and temperature-controlled home collection, post-result telephonic clinical interpretation, and instant insurance verification via WhatsApp.
Accuracy Guarantee: 99.9% Diagnostic Sensitivity, ISO-Accredited Processing
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection
Clinical Guidance: Telephonic Post-Test Interpretation by Specialist Team
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
This advanced genetic test uses Next‑Generation Sequencing (NGS) to detect somatic mutations in the KRAS gene, a critical biomarker in acute myelogenous leukemia (AML) that influences prognosis and targeted therapy selection.
| Feature | Our KRAS NGS Test | Closest Alternative (Single‑Gene PCR) |
|---|---|---|
| Methodology | NGS – high‑coverage, simultaneous analysis of all coding exons | Sanger sequencing or targeted PCR – limited to hotspot regions |
| Sensitivity & Clinical Utility | Detects variants down to 1% allele frequency; identifies rare mutations critical for AML prognosis and targeted therapy | Lower sensitivity (~10‑20%), may miss subclonal mutations |
| Turnaround Time (TAT) | 3–4 Weeks | 2–3 Weeks |
| Price | 2,800 AED | 1,500–2,000 AED (limited scope) |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I understand the importance of precise genetic characterization in AML. This NGS assay provides comprehensive KRAS mutation profiling, essential for guiding personalized treatment strategies. However, results must always be integrated with clinical findings and hematology consultation. Never discontinue prescribed medications without physician approval.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Notice
⚠ Genetic Result Advisory
Do not alter or discontinue prescribed therapy based solely on genetic findings. All results must be interpreted by a qualified specialist in context of your full medical profile.
Exclusion Criteria & Emergency Red Flags
- Severe anemia (Hb < 7 g/dL) requiring prior transfusion; discuss with your physician before sample collection.
- Active systemic infection – blood draw should be deferred until resolution.
- Pregnancy – discuss the necessity and timing of genetic testing with your obstetrician.
🩺 Seek emergency care immediately if you experience sudden severe bleeding, uncontrolled fever, or signs of sepsis (confusion, rapid breathing) while waiting for results.
Patient FAQ & Clinical Guidance
1. What is the KRAS Gene NGS Test for AML and how does it help in treatment?
This test detects KRAS gene mutations in AML cells using next‑generation sequencing, guiding targeted therapy decisions and prognosis. By identifying specific mutations within the KRAS gene, your oncologist can better predict disease behavior and consider therapies that specifically target the RAS pathway. The NGS technology ensures even low‑level mutations are captured, offering a comprehensive view that single‑gene tests might miss.
2. How long do results take and what is the home collection process in Dubai?
Results are delivered within 3–4 weeks from sample collection via blood draw or FTA card at home by a licensed phlebotomist. A DHA‑licensed phlebotomist arrives at your scheduled time (8 AM‑11 PM), collects a small blood sample or finger‑prick drop on an FTA card, and transports it under strict cold‑chain conditions. You will receive a secure digital report with an interpretive summary once analysis is complete.
3. Is the KRAS NGS test covered by insurance in the UAE and how can I verify?
Many UAE insurers cover medically necessary genetic testing; we verify coverage directly via WhatsApp within minutes. Before your appointment, send a photo of your insurance card and Emirates ID to +971 54 548 8731. Our billing team confirms eligibility and any co‑payment requirements instantly, ensuring a transparent, stress‑free experience in line with UAE healthcare regulations.
UAE Regulatory & Data Privacy Adherence
Data Protection & Legal Compliance
This test and its associated data handling fully comply with:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Federal Decree‑Law No. 4 of 2016 on Medical Liability (patient consent and safety)
Laboratory is ISO 9001:2015 Certified – Certificate: INT/EGQ/2509DA/3139.
Results must be reviewed by a qualified clinician. This page does not constitute medical diagnosis.
Clinical & Logistical Metadata
| Test Name | KRAS Gene Mutation Analysis for Acute Myelogenous Leukemia (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (or FTA Card) |
| Methodology Used | Next‑Generation Sequencing (NGS) |
| ICD‑10‑CM Code | C92.00 |
| LOINC Code | 21659-8 |
| DHA Facility License & Address | License No. 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE (DNA Labs UAE) |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians